Janus kinase inhibitors

Evaluating Reduced Versus Standard Dosing of Janus Kinase Inhibitors in Rheumatoid Arthritis: Insights from a Propensity Score-Matched Real-World Study

By MedXY 10/26/2026

A real-world Japanese study finds comparable 24-month treatment persistence between reduced and standard dosing of JAK inhibitors in rheumatoid arthritis patients with preserved renal function, with dose considerations influenced by poor prognostic factors and renal status.

Hematology-Oncology news

Janus Kinase Inhibitors: Transforming Treatment Paradigms in Lymphomas and Immune-Mediated Complications

By MedXY 08/26/2026

Janus kinase inhibitors have emerged as pivotal agents in managing lymphoid malignancies and associated immune complications, offering new therapeutic avenues shaped by molecular insights into the JAK/STAT pathway.

Allergy & Immunology Dermatology news

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

By MedXY 07/12/2026

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their impact on efficacy, safety, and cost.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.